MedTrace Logo

Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

NCT02785250 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2021-06-18

No results posted yet for this study

Summary

T cell activating therapy DPX-Survivac, low dose oral cyclophosphamide, and IDO1 inhibitor epacadostat will be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to determine the safety and potential immune-modulating activity of the combination of these agents.

Conditions

  • Recurrent Epithelial Ovarian Cancer
  • Recurrent Fallopian Tube Cancer
  • Recurrent Peritoneal Cancer

Interventions

OTHER

DPX-Survivac

SubQ injection

DRUG

Cyclophosphamide

PO BID

DRUG

Epacadostat (INCB024360)

PO BID

Sponsors & Collaborators

  • Incyte Corporation

    collaborator INDUSTRY

  • ImmunoVaccine Technologies, Inc. (IMV Inc.)

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2020-10-31
Completion
2025-05-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02785250 on ClinicalTrials.gov